

FOR IMMEDIATE RELEASE

February 8, 2005

Additional information contact:

Michael Smyser
MD Systems, Inc.
P.O. Box 1647
Westerville, Ohio 43086
(614) 818-3000
www.cardiogrip.com
masmyser@mdsystems.com

CARDIOGRIP BLOOD PRESSURE MANAGEMENT DEVICE SPURS NEW JOINT VENTURE

Columbus, Ohio — MD Systems, Inc. announced the formation of CardioGrip Corporation, an Idaho based company, to establish CardioGrip therapy as a recognized standard of care for the early treatment of hypertension. The patented CardioGrip® device, developed by MD Systems, is the first FDA cleared isometric exercise device clinically proven to lower high blood pressure. CardioGrip is a sophisticated hand dynamometer that guides users through regulated isometric handgrip exercises, invented by Dr. Ronald L. Wiley at Miami University, Oxford, Ohio.

Numerous clinical trials, highlighted by recent studies at medical centers of Ohio State University and McMaster University in Canada, validate that CardioGrip exercise training protocols lower blood pressure with efficacy rates approaching 100 percent. McMaster University studies also have validated that using CardioGrip therapy leads to lasting physiological changes which alter blood pressure. The CardioGrip device is very portable, making it convenient to use in the office, while traveling as a passenger in a car or plane, while watching TV, or anytime the hands are free. Daily use is 12 minutes.

CardioGrip Corporation is a joint venture project between Columbus-based MD Systems and Intermountain Management Group of Idaho, a business development company specializing in the successful formation and growth of medical device companies. Privately-held CardioGrip Corporation began operations in Eagle, Idaho on January 1, 2005, with initial funding commitments of \$2.5 million.

CardioGrip Corp. plans to establish the CardioGrip therapy as a preferred initial standard of care by medical professionals for high normal and Stage 1 hypertension patients—more than 80 million in the

U.S. alone. Hypertension management for the 12 million Americans taking drugs for their high blood pressure costs \$11 billion annually while the price of the CardioGrip unit is less than half the average yearly cost of a patient's blood pressure medications. The National Institutes of Health (NIH) recommends hypertension drugs be used as a last resort due to side effects. CardioGrip therapy eliminates side effects by utilizing the body's own mechanisms to control blood pressure through stimulation of the cardiovascular systems vessel walls.

Studies of the CardioGrip therapy have demonstrated group average reductions of 12mm to 19mm with individual patient responses ranging from 5mm to 40mm drops. CardioGrip Corp. will sponsor a 500 patient nationwide study in centers of medical excellence during 2005. These results and subsequent journal publications, are expected to expand the scope of CardioGrip application within diverse hypertensive and high normal populations. The worldwide market for CardioGrip products exceeds 980 million people with high blood pressure in industrialized countries.

Detailed information on CardioGrip Corporation and its products may be reviewed on-line at www.cardiogrip.com or by calling 877-863-4927 toll free.

###